Alatawi Abdullah, Kho SoonJye, Markey Michael P
Department of Biochemistry and Molecular Biology, Wright State University, Dayton, OH 45435, USA.
Department of Computer Science and Engineering, Wright State University, Dayton, OH 45435, USA.
J Skin Cancer. 2021 Oct 16;2021:3087579. doi: 10.1155/2021/3087579. eCollection 2021.
The p53 tumor suppressor integrates upstream signals such as DNA damage and active oncogenes to initiate cell cycle arrest or apoptosis. This response is critical to halting inappropriate growth signals. As such, p53 activity is lost in cancer. In melanoma, however, the p53 gene is intact in a reported 94% of human cases. Rather than direct mutation, p53 is held inactive through interaction with inhibitory proteins. Here, we examine the expression of the two primary inhibitors of p53, MDM2 and MDM4, in genomic databases and biopsy specimens. We find that MDM4 is frequently overexpressed. Moreover, changes in splicing of MDM4 occur frequently and early in melanomagenesis. These changes in splicing must be considered in the design of therapeutic inhibitors of the MDM2/4 proteins for melanoma.
p53肿瘤抑制蛋白整合诸如DNA损伤和活跃癌基因等上游信号,以启动细胞周期停滞或凋亡。这种反应对于阻止不适当的生长信号至关重要。因此,p53活性在癌症中丧失。然而,在黑色素瘤中,据报道94%的人类病例中p53基因是完整的。p53并非直接发生突变,而是通过与抑制蛋白相互作用而保持无活性状态。在此,我们在基因组数据库和活检标本中检测了p53的两种主要抑制剂MDM2和MDM4的表达。我们发现MDM4经常过度表达。此外,MDM4的剪接变化在黑色素瘤发生过程中频繁且早期出现。在设计针对黑色素瘤的MDM2/4蛋白治疗性抑制剂时,必须考虑这些剪接变化。